市場調查報告書
商品編碼
1298859
體外大腸癌篩查測試市場:2023-2028年全球行業趨勢、佔有率、規模、成長、機會和預測In-vitro Colorectal Cancer Screening Tests Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 |
2022年,全球體外結直腸癌篩查測試市場規模達到9.43億美元。展望未來,IMARC Group預計,到2028年,市場規模將達到13.52億美元,在2023-2028年期間呈現5.8%的成長率(CAGR)。
體外結直腸癌篩查試驗是為檢測腺瘤、息肉和結直腸癌症狀而進行的診斷程序。大腸癌是指一種以大腸、結腸和直腸細胞異常生長為特徵的醫學症狀。糞便隱血(FOB)、側向流免疫、轉鐵蛋白檢測、甲基化基因、生物標記和guaiac FOB糞便檢測是一些通常進行的篩查測試。體外結直腸癌篩查測試涉及到使用鏡頭捕捉消化道的圖像,並將其傳輸到綁在病人腰部的記錄器。它們是微創性的,可以幫助及時發現癌症。因此,體外大腸癌篩查試驗在診所、醫院和診斷實驗室廣泛開展。
結直腸癌在群眾中的發病率越來越高,這是推動市場成長的關鍵因素之一。此外,人們對早期發現和及時治療癌症的好處的認知不斷提高,對市場的成長產生了積極的影響。各種技術進步,如癌症篩查測試中的基因測試的整合,正在為市場成長提供推動力。這些測試有助於早期檢測,制定治療計劃,防止癌細胞擴散,最大限度地減少相關疾病的風險。與此相應,越來越多的人傾向於採用微創(MI)診斷程序來檢測結直腸癌,這有利於市場的成長。其他因素,包括老年人口的增加,更容易受到這種疾病的影響,醫療保健行業的顯著改善,以及各種政府計劃的實施,強制癌症篩查測試,預計將推動市場的成長。
The global in-vitro colorectal cancer screening tests market size reached US$ 943 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 1,352 Million by 2028, exhibiting a growth rate (CAGR) of 5.8% during 2023-2028.
In-vitro colorectal cancer screening tests are diagnostic procedures performed to detect adenomas, polyps and symptoms of colorectal cancer. Colorectal cancer refers to a medical condition that is characterized by the abnormal growth of cells in the large intestine, colon and rectum. Fecal occult blood (FOB), lateral flow immuno, transferrin assays, methylated gene, biomarker and guaiac FOB stool test are some of the commonly performed screening tests. In-vitro colorectal cancer screening tests involve the use of cameras that capture images of the digestive tract and transfers them to the recorder tied to the waist of the patient. They are minimally invasive and can aid in timely detection of cancer. As a result, in-vitro colorectal cancer screening tests are widely performed across clinics, hospitals and diagnostics laboratories.
The increasing prevalence of colorectal cancer among the masses is one of the key factors driving the growth of the market. Moreover, rising awareness regarding the benefits of early detection and timely treatment of cancer is positively impacting the market growth. Various technological advancements, such as the integration of genetic testing in cancer screening tests, are providing a thrust to the market growth. These tests aid in early detection, developing treatment plans, preventing the spread of cancerous cells and minimizing the risks of developing associated disorders. In line with this, the increasing preference for minimally invasive (MI) diagnostic procedures to detect colorectal cancer is favoring the market growth. Other factors, including rising geriatric populations, which is more susceptible to such ailments and significant improvements in the healthcare industry, along with the implementation of various government initiatives mandating cancer screening tests, are anticipated to drive the market toward growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global In-vitro colorectal cancer screening tests market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product, imaging type and end user.
Fecal Occult Blood Tests
Guaiac FOB Stool Test
Immuno-FOB Agglutination Test
Lateral Flow Immuno-FOB Test
Immuno-FOB ELISA Test
Biomarker Tests
Tumor M2-PK Stool Test
Transferrin Assays
CRC DNA Screening Tests
Methylated Gene Testing
Panel DNA Tests
Colonoscopy
Proctoscopy
CT Scan
Ultrasound
MRI
PET Scan
Hospitals
Clinics
Diagnostic Laboratories
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Beckman Coulter Inc. (Danaher Corporation), Eiken Chemical Co. Ltd., Epigenomics AG, Exact Sciences Corporation, Hemosure Inc., Immunostics Inc. (Boditech Med Inc.), Medline Industries LP, Merck KGaA, Qiagen N.V., Quest Diagnostics Incorporated, R-Biopharm AG, Siemens AG and Sysmex Corporation.
Key Questions Answered in This Report
1. What was the size of the global in-vitro colorectal cancer screening tests market in 2022?
2. What is the expected growth rate of the global in-vitro colorectal cancer screening tests market during 2023-2028?
3. What has been the impact of COVID-19 on the global in-vitro colorectal cancer screening tests market?
4. What are the key factors driving the global in-vitro colorectal cancer screening tests market?
5. What is the breakup of the global in-vitro colorectal cancer screening tests market based on the product?
6. What is the breakup of the global in-vitro colorectal cancer screening tests market based on the imaging type?
7. What is the breakup of the global in-vitro colorectal cancer screening tests market based on end user?
8. What are the key regions in the global in-vitro colorectal cancer screening tests market?
9. Who are the key players/companies in the global in-vitro colorectal cancer screening tests market?